These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27021610)

  • 1. Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar.
    Al-Badriyeh D; Alabbadi I; Fahey M; Al-Khal A; Zaidan M
    Clin Ther; 2016 May; 38(5):1158-73. PubMed ID: 27021610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference.
    Al-Badriyeh D; Fahey M; Alabbadi I; Al-Khal A; Zaidan M
    Clin Ther; 2015 Dec; 37(12):2798-810. PubMed ID: 26299479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulary management of proton pump inhibitors.
    Byrne MF; Murray FE
    Pharmacoeconomics; 1999 Sep; 16(3):225-46. PubMed ID: 10558037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of nonformulary use of PPIs and excess drug cost in a Veterans Affairs population.
    Ajumobi AB; Vuong R; Ahaneku H
    J Manag Care Pharm; 2012; 18(1):63-7. PubMed ID: 22235956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
    McNicholl AG; Linares PM; Nyssen OP; Calvet X; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):414-25. PubMed ID: 22803691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
    Linton A; Bacon T; Peterson M
    J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
    Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
    Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
    van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
    Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
    Clark DW; Strandell J
    Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
    Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
    Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar.
    Awaisu A; Hamou F; Mekideche L; El Muabby N; Mahfouz A; Mohammed S; Saad A
    Int J Clin Pharm; 2016 Apr; 38(2):353-61. PubMed ID: 26749343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
    Tsai CF; Chen MH; Wang YP; Chu CJ; Huang YH; Lin HC; Hou MC; Lee FY; Su TP; Lu CL
    Gastroenterology; 2017 Jan; 152(1):134-141. PubMed ID: 27639806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
    Chen G; Ning LJ; Qin Y; Zhao B; Mei D; Li XM
    J Gastroenterol Hepatol; 2021 Jan; 36(1):156-162. PubMed ID: 32542684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
    Edwards SJ; Lind T; Lundell L
    Aliment Pharmacol Ther; 2006 Sep; 24(5):743-50. PubMed ID: 16918878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole.
    Qi F; Zhu L; Li N; Ge T; Xu G; Liao S
    Int J Antimicrob Agents; 2017 Apr; 49(4):403-409. PubMed ID: 28159656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
    Kirchheiner J; Glatt S; Fuhr U; Klotz U; Meineke I; Seufferlein T; Brockmöller J
    Eur J Clin Pharmacol; 2009 Jan; 65(1):19-31. PubMed ID: 18925391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Modified System of Objectified Judgement Analysis (SOJA) methodology on prescribing costs of ACE inhibitors.
    Alabbadi I; Crealey G; Scott M; Baird S; Trouton T; Mairs J; McElnay J
    Clin Drug Investig; 2006; 26(9):485-94. PubMed ID: 17163281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
    Robinson M; Horn J
    Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.